02511 HIGHTIDE-B
- 5.110
- -0.180-3.40%
HIGHTIDE-B News
Closing up 42% at the end of the session, is it still too early to say that Junshengtai Pharmaceutical-B (02511) broke out of the trough?
With high investment in R&D, capital consumption will also increase. Whether the current cash can support the commercialization of Junshengtai's core products is still unknown.
君聖泰醫藥-B：2023年報
Changes in Hong Kong stocks | Junshengtai Pharmaceutical-B (02511) once rose more than 42% and previously announced the completion of the phase IIb clinical trial of HTD1801 to enroll patients
Junshengtai Pharmaceutical-B (02511) once rose by more than 42%. As of press release, it rose 23.49% to HK$5.31, with a turnover of HK$12.3888 million.
HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator
HighTide Therapeutics (HKG:2511) has completed patient enrollment for the Phase II-b clinical trial of HTD1801, a gut-liver anti-inflammatory metabolic modulator, a Wednesday filing on the Hong Kong b
Junshengtai Pharmaceutical-B (02511.HK): HTD1801 clinical trial to treat metabolic steatohepatitis (MASH) phase IIb completed patient enrollment
Gelonghui, April 3 | Junshengtai Pharmaceutical-B (02511.HK) announced that the Phase IIb clinical trial of the enterohepatic anti-inflammatory and metabolic regulator HTD1801 (Xiongdeoxycholic Berberberis), developed independently by the company, has enrolled patients. The trial targets patients with metabolic fatty hepatosis (MASH for short) with type 2 diabetes (T2DM) or pre-diabetes. This trial (Centricity study) is a randomized, double-blind, placebo-controlled global multicenter phase IIb clinical trial aimed at evaluating HTD1801 in
Junshengtai Pharmaceutical-B (02511) released annual results, R&D costs of 312 million yuan, an increase of 70.6% over the previous year
Junshengtai Pharmaceutical-B (02511) announced 2023 results, other revenue and revenue of 34.2 million yuan (people...
HIGHTIDE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
HIGHTIDE-B: NOTICE OF DATE OF BOARD MEETING
Junshengtai Pharmaceutical-B (02511): Li Li resigns as non-executive director
Zhitong Finance App News, Junshengtai Pharmaceutical-B (02511) issued an announcement. Li Li has resigned as a non-executive director due to his intention to invest more time in his personal affairs, with effect from February 2, 2024.
HighTide Therapeutics to Set Up New Plant in China Expansion Plans
HighTide Therapeutics (HKG:2511) intends to establish a new northern China operational base and material production facility as part of plans to expand in China's Hebei Province. The biopharmaceutical
Selected Announcements | China Merchants Bank's net profit last year exceeded 146.6 billion yuan; China Telecom's 5G users increased by 50.7 million last year
Haifeng International issued a profit warning. The profit due to shareholders in 2023 is expected to be about 530 million US dollars, down about 73% from the previous year; Zero Sports Auto will issue H shares and domestic shares to raise up to 600 million yuan.
Junshengtai Pharmaceutical-B (02511.HK) plans to expand its business layout to Hebei Province
Gelonghui, January 19 | Junshengtai Pharmaceutical-B (02511.HK) announced that the Group plans to expand its business layout to Hebei Province, China. Currently, the Group has offices and R&D centers in Shenzhen, Shanghai, Nanchang and Hong Kong. Through the expansion of its business layout in Hebei Province, the Group expects to attract top talents with strong academic backgrounds and industry experience in North China to further strengthen and enrich the Group's industry and regulatory registration resources and/or raw material supply capacity. Possible business expansion measures include the establishment of a new North China cooperative planning, registration management and/or raw material production and operation base. The above business
[IPO] Junshengtai Pharmaceutical (02511) closed at HK$12.38, 7.65% higher than the offering price
Jinwu Financial News | Junshengtai Pharmaceutical (02511) initially closed at HK$12.38, 7.65% higher than the prospectus price. It traded 5.1065 million shares throughout the day, with a turnover of HK$61,5793 million. No handling fees, 500 shares per lot, a book profit of HK$440. The stock was reported at HK$11.92 in early trading, 3.65% higher than the tender price. The full day high was HK$16.68, and the lowest price was HK$11.92. The latest total market value is HK$6.373 billion.
Hightide Therapeutics Gains 7% in Hong Kong Trading Debut
Hightide Therapeutics (HKG:2511) gained 7.7% in its trading debut in Hong Kong on Friday, Dec. 22. The integrated biopharmaceutical company opened HK$11.92 per share, higher than its initial public of
[IPO] Junshengtai Pharmaceutical (02511) priced at HK$11.5, first-hand winning rate 13.65%
Jinwu Financial News | Junshengtai Pharmaceutical (02511) announced that the final sale price was set at HK$11.5 per share, with total capital raised proceeds of HK$278 million. The subscription amount for public sales is 32.22 times, and the subscription amount for international placement is 1.25 times. Each lot has 500 shares, and the first-lot winning rate is 13.65%. If you subscribe for 9 lots, you can get one lot steadily.
Junshengtai Pharmaceutical-B (02511) was publicly sold and is expected to be listed on December 22 by 32.22 times
Junshengtai Pharmaceutical-B (02511) announced the allotment results. The company sold 24.194 million shares globally, making a public offering...
Hepalink Pharma Associate HighTide Therapeutics to Debut in Hong Kong on Friday
HighTide Therapeutics (HKG:2511) is expected to begin trading on the Hong Kong bourse on Friday, Dec. 22. Established in 2011, the biopharmaceutical company specializes in the discovery, development,
[IPO] Junshengtai Pharmaceutical-B (02511) Starting today, the IPO fee is HK$5807.99
Jinwu Financial News | Junshengtai Pharmaceutical-B (02511) starts offering shares today and plans to issue 24.194 million shares, of which 10% will be publicly sold in Hong Kong and the rest will be placed internationally. The offer price per share is HK$11.5, 500 shares per lot, and the entry fee is HK$5807.99. The shares are expected to be listed on December 22. Junshengtai Pharmaceutical is a biopharmaceutical company that focuses on the discovery, development and commercialization of multifunctional and multi-target therapies for the treatment of metabolic and digestive diseases. The company plans to use about 80% of the net capital raised proceeds for the core product HTD1801 to fund its ongoing clinical trials
Analysis
Price Target
No Data
